In addition, DNMT3A mutations are frequently accompanied by TET2 mutations (in 70%~100% of AITL cases), showing synergistic effects on lymphomagenesis despite having opposite epigenetic effects (14). The gene discussed is DNMT3A; the disease is angioimmunoblastic T-cell lymphoma.